Georgia Tech Research Corp., Atlanta, Georgia, was awarded a $9,284,660 cost reimbursement contract to develop and manufacture a point-of-need pathogen detection technology that will identify the underlying pathogens responsible for the human diseases of sepsis (bacteremia) and respiratory infection, as well as meet Food and Drug Administration requirements for regulatory approval. This two-year contract includes five options which, if exercised, would bring the potential value of this contract to $24,582,734 and a period-of-performance of four years. Work will be performed at the contractor’s facilities in Atlanta, Georgia (46%); Boston, Massachusetts (29%); Thurleigh, United Kingdom (19%); and Daresbury, United Kingdom (6%). The period of performance of the base award is from July 18, 2022, through July 17, 2024. If all option periods are exercised, the period of performance would extend through July 17, 2026. Contract funds in the amount of $3,607,000 will be obligated at the time of award. This contract was competitively procured via a Defense Advanced Research Projects Agency broad agency announcement solicitation (HR001120S0016) published on the beta.sam.gov website. Seven proposals were received and two were selected for award. Naval Information Warfare Center Pacific, San Diego, California, is the contracting activity (N66001-22-C-4012). (Awarded July 14, 2022)
Recommended
free preview